Best of ASCO - 2014 Annual Meeting



Advanced Disease

Gastrointestinal (Colorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.

Pashtoon Murtaza Kasi


A novel RAS internal tandem duplication involving the switch II domain disrupts GAP-binding and activates oncogenic signaling.

Emil Lou


A phase I clinical trial of fluorouracil (5-FU) + devimistat (CPI-613) combination in previously treated patients (pts) with metastatic colorectal cancer (MCR).

Caio Max Sao Pedro Rocha Lima


A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO).

Joleen Marie Hubbard


A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic MSS colorectal cancer (CRC): A postoperative safety analysis.

Michael Frederick Bassetti


A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.

Arthur Winer


A phase II study of apatinib combined with S-1 in previously treated refractory metastatic colorectal cancer.

Ning Li


A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).

Aparna Raj Parikh


A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).

Hirokazu Shoji


A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).

Stefan Kasper


A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.

Filippo Pietrantonio


A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.

Carl Christoph Schimanski


A regulatory program that promotes metastasis in colorectal cancer (CRC) through modulation of mRNA stability.

Hani Goodarzi


Add-on anti-vascularendothelial growth factor agents with the second-line chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized trials.

Feng-Che Kuan


Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): Clinical predictors of nonhematologic (nonhem) toxicity.

Liubov Yu Vladimirova


Aggressiveness of care and overall survival in young metastatic colorectal cancer patients.

Madeleine Fish


Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study.

Ibrahim Halil Sahin


Apatinib combined with Raltitrexed in patients with metastatic colorectal cancer after failure of standard therapy (AHEAD-311): A single-arm phrase II pilot trial.

Haiyan Si


Apatinib monotherapy for chemotherapy-refractory metastatic colorectal cancer: A multicenter, single-arm, prospective study.

Fen Wang


Association between gene fusions and anti-EGFR resistance signature in colorectal cancer.

Thereasa A. Rich


Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial.

Jin Li


Association of co-occuring mutations in exosomal DNA and clinical outcomes of patients with metastatic colorectal cancer.

Chuanhua Zhao


Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.

Lisa Salvatore


Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.

James Isaacs


CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).

Eric Xueyu Chen


Cetuximab maintenance therapy in unresectable metastatic colorectal cancer patients with wild-type RAS and BRAF: A single-center retrospective study.

Tao Jiang


cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study.

Alexandre Harle


Characteristics and outcomes of patients with colorectal cancer and bone metastasis.

Faisal Shahjehan


Chemotherapy rechallenge or reintroduction (CTr/r), regofenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients (pts): A propensity score analysis of treatment beyond second-line (PROSERpINA Study).

Maria Alessandra Calegari


Circulating tumor DNA dynamics, serial testing and evolution on treatment in 322 colorectal cancer patients.

Pashtoon Murtaza Kasi


Circulating tumor DNA-based mutational landscape of advanced colorectal cancer.

Fang Yan


Clinical efficacy and safety evaluation of nimotuzumab combined with chemotherapy in the treatment of advanced colorectal cancer: A retrospective analysis.

Sai-xi Bai


Clinical significance of ZHX2 in colitis and colorectal carcinogenesis.

Yonghua Bao


Clinical, pathological and prognostic features of rare BRAF mutations (MTs) in metastatic colorectal cancer (mCRC): A bi-institutional retrospective analysis (REBUS study).

Brunella Di Stefano


Clinicopathologic predictors of worse outcome in early onset colorectal cancer (EO-CRC): A single-institution experience.

Devika Rao


Colorectal cancer lung metastasis: Could multidisciplinary management suggest the right strategy?

Ina Valeria Zurlo


Comprehensive transcriptome analysis reveals link between epigenetic dysregulation, endogenous retrovirus expression and immunogenicity in metastatic colorectal carcinoma.

Shehara Ramyalini Mendis


Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO-KRK-0109).

Stefanie Noepel-Duennebacke


Cost and effectiveness of genetic testing in metastatic colorectal cancer (mCRC) at Montefiore Medical Center (MMC).

Nadia Ashai


Cost-effectiveness for metastatic colorectal cancer.

Linli Yao


ctDNA as a potential prognostic marker for locally advanced rectal cancer patients with ‘watch and wait’ approach.

Lifeng Yang


Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18F-FDG PET/CT and clinical factors for metastatic colorectal cancer patients.

Erwin Woff


Effect of acid-reducing agents on the efficacy of capecitabine in metastatic gastrointestinal cancers.

Tonjeh Mary Stella Bah


Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306).

Volker Heinemann


Efficacy of anti-EGFR-based treatment (tx) in second-line and beyond according to tumor location (TL) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A mono-institutional retrospective analysis.

Raffaella Vivolo


Efficacy of PD-1/PD-L1 inhibitor-based therapies in refractory microsatellite instability (MSI)-unselected metastatic colorectal cancer (mCRC): A network meta-analysis (NMA) of randomized controlled trials (RCTs).

Zi-xian Wang


Efficacy of quxie capsule in metastatic colorectal cancer: Update of a double-blind, randomized, placebo controlled trial.

Tong Zhang


Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.

Daniele Rossini


Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.

Ofer Margalit


Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).

Kaysia Ludford


Evaluation of Dworak grading system as a prognostic indicator after neoadjuvant chemoradiotherapy in rectal cancer patients.

Rebecca Buecker


Evaluation of long term survival in pretreated metastatic colorectal cancer patients undergoing GOLFIG chemoimmunotherapy regimen.

Pierpaolo Correale


Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients.

Ina Valeria Zurlo


Feasibility of a national expert panel to determine resectability in patients with initially unresectable colorectal cancer liver metastases (CRLM).

Karen Bolhuis


Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).

Michael Geissler


FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis.

Alexandre A Jacome


Fruquintinib or regorafenib as the third-line treatments for metastatic colorectal cancer based on CONCUR and FRESCO trials: A cost-effectiveness analysis.

Qiu Li


Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.

Kathrin Heinrich


Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.

Hiroyuki Arai


Genomic alterations after EGFR blockade in patients with RAS wild-type metastatic colorectal cancer: Combined tissue and blood-based analysis from SCRUM-Japan GI-SCREEN and GOZILA.

Yoshiaki Nakamura


HD204: Analytical biocomparability and clinical trial I progression of bevacizumab.

Jocelyn hii


How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis.

Antonio Galvano


Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.

Federica Marmorino


Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.

Gemma Zucchelli


Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia.

Mikhail Fedyanin


Intratumoral CD3+ and CD8+ T-cell densities in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC) receiving programmed death-1 (PD-1) blockade.

Sakti Chakrabarti


Investigation of an ethnic predisposition to developing brain metastases (BM) in Asian patients with colorectal cancer (CRC).

Kerri McGovern


Long-term survival after laparoscopic versus open resection for colorectal liver metastases.

Åsmund Avdem Fretland


Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.

Thiru Prasanna


Microsatellite instability and mutations in BRAF and KRAS in small bowel adenocarcinoma.

Vasiliki Michalaki


Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).

Sukeshi Patel Arora


Mutational burden on circulating cell-free tumor-DNA testing as a surrogate marker of mismatch repair deficiency/microsatellite instability and/or response to immunotherapy in patients with colorectal cancer.

Saivaishnavi Kamatham


Mutational profiles and amplifications on circulating tumor DNA testing in patients with young-onset colorectal cancer.

Saivaishnavi Kamatham


Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.

Heinz-Josef Lenz


Outcomes of metastatic colorectal cancer over fifteen years from an Indian tertiary care center: A retrospective analysis.

Vinod Sharma


Patterns of metastasis and second primary malignancies (SPM) in colorectal cancer: A perspective from Peru.

Jorge Leon


Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal).

Frederic Dumont


Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.

Ramon Salazar


POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.

David Lau


Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.

Toshiki Masuishi


Predictors of survival in chemorefractory colorectal liver metastases treated with Y90 radioembolization.

Alexander Michael Dabrowiecki


PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy.

Valerie Boige


Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies.

Julien Taieb


Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs).

Enrique Aranda


Randomized phase II trial of adjuvant hepatic arterial infusion (HAI) + systemic FOLFIRI +/- panitumumab (Pmab) in patients with resected RAS wild type colorectal cancer hepatic metastases (CRLM).

Nancy E. Kemeny


Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).

Javier Sastre


RAS-amplified colorectal cancers: Microsatellite stability status, RAS/BRAF mutations, and prediction of anti-EGFR resistance.

Alexa Betzig Schrock


Recent changes in overall survival of real-life stage IV colorectal cancer patients.

Patricia Hamers


Rectal cancer and pathologic complete response after preoperative chemoradiotherapy: Romanian single-center experience.

Eduard-Alexandru Bonci


Repeated centralized MDT resectability assessment during first-line treatment in 1086 Finnish metastatic colorectal cancer (mCRC) patients nationwide (prospective RAXO study).

Pia J. Osterlund


Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization.

Robert Asa Horn


ROCKET: A randomized, multicenter phase 2 study of RRx-001 + irinotecan versus regorafenib in 3rd/4th line colorectal cancer.

Tony R. Reid


Screening patients for fluoropyrimidine-related toxicity risk.

Olivier Capitain


Stereotactic body radiotherapy (SBRT) for colorectal liver metastasis: Clinical outcomes from the international multi-institutional RSSearch Patient Registry.

Pollyanna D'Avila Leite


Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastases from colorectal cancer.

Stein G Larsen


Survival after primary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (FFCD ACHBTH AURC 9002 trial and EORTC Intergroup trial 40983).

Carl Christoph Schimanski


Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).

Markus Hermann Moehler


The “effect” of T classification on colorectal liver metastasis.

Lunpo Wu


The efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer (ACC) patients: An interim analysis of a multicenter, phase II trial.

Yunpeng Liu


The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Maryam B. Lustberg


The impact of nodal metastasis on survival in stage IV colon cancer: Analysis of National Cancer Database 2004-2014.

Sukamal Saha


The role of maintenance strategy in metastatic colorectal cancer (mCRC): A systematic review and meta-analysis.

Mohamad Bassam Sonbol


Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers.

Gemma Bruera


Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial.

Eiji Oki


Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109).

Dominik Paul Modest


Type 2 diabetes as a potential risk marker for early onset colorectal cancer.

Joanne Young


Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

Chiara Cremolini


Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder.

Reese Garcia


Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Franck Pages


Who can benefit from a liver surgery for metastatic colorectal cancer in the era of modern chemotherapy? A post hoc analysis of the MIROX phase III trial.

Samira Makhloufi


Young-onset colorectal cancer patients disproportionately diagnosed with advanced disease: Patient self-reported journey of symptom duration and misdiagnosis.

Ronit Yarden